The modification was not designed to add a capability. It was designed to remove a brake — and growth signals do not discriminate between tissues.
IGF-1 LR3 is a redesigned version of a hormone your liver already makes. Two changes separate it from the original, and both were made for the same reason: to stop the body regulating it.
Native IGF-1 is 70 amino acids long. This version runs to 83. One change swaps the amino acid at position 3, putting arginine where glutamic acid was. The other adds thirteen residues to one end.
Those sound like small edits. They are not, because of what they defeat.
When your liver releases IGF-1, most of it is captured almost at once by IGF binding proteins. These work as chaperones. They carry the hormone through the bloodstream. They control how much is free to reach receptors at any moment. And they hold its working half-life to somewhere around 12 to 15 hours.
That capture is regulation. It is how the body keeps a powerful growth signal on a leash.
The LR3 changes give the molecule very low affinity for those binding proteins. It circulates largely unbound, and therefore active. Reported results are roughly three times the potency of native IGF-1, and a half-life stretched to something like 20 to 30 hours.
So the design goal was not to add a new capability. It was to remove a brake.
The IGF-1 receptor is a receptor tyrosine kinase — the same family as the insulin receptor, and not the GPCR family most peptide hormones use.
Binding causes the receptor to phosphorylate itself, which starts two cascades:
PI3K-Akt-mTOR drives protein synthesis and supports cell survival. It also increases glucose uptake into muscle. And it slows protein breakdown, by blocking the enzymes that tag proteins for disposal. This is where the muscle-building effect comes from.
MAPK drives cell division and differentiation. Where the first pathway builds, this one multiplies.
Most anabolic compounds enlarge existing muscle fibres. IGF-1 does that, and something else besides.
Hypertrophy is the familiar route: more protein synthesis, larger fibres.
Satellite cell activation is the second. Satellite cells are muscle's resident stem cells. Activated, they fuse into existing fibres and add nuclei, expanding the cellular machinery available to support growth.
How much does each contribute? A 1999 experiment answered this cleanly by disabling satellite cell function with radiation and repeating the IGF-1 treatment. The growth response fell by roughly half. So about half the effect runs through satellite cells and half through direct action on existing fibres.
That is a genuinely unusual property, and it is the strongest thing in the compound's case.
Very little, and none of it with this modified version.
A 1994 study infused native IGF-1 into the artery supplying the forearm in healthy volunteers. Muscle protein synthesis rose 49 to 74%, protein breakdown fell by around 45% at higher doses, and blood flow increased substantially. The author's conclusion was that IGF-1 shows both growth-hormone-like and insulin-like actions on human muscle.
That is a controlled infusion into one limb, measuring biochemistry over hours. It is not a study of injecting a modified analogue for weeks.
A 1997 study in pigs and marmosets confirmed the change works as intended. Variants with poor binding-protein affinity were two to three times more potent than native IGF-1 at lowering blood sugar. Their cumulative effect was four to eight times greater. That is the pharmacology working. It is also a warning, because the property being measured is blood sugar crashing.
This is the most useful mechanistic point here, because it explains why a common combination is self-defeating.
Raising circulating IGF-1 triggers the hypothalamus to release somatostatin, whose job is to stop the pituitary responding to growth-hormone-releasing signals. That is the body's feedback loop doing exactly what it exists to do.
Secretagogues work by sending those very signals. Research on growth hormone autofeedback found GHRH-pathway responses inhibited by around 86%, and ghrelin-pathway responses blunted by roughly a third.
So running both means paying for two compounds while the first one silences the second. The mechanisms are not complementary; they are opposed.
Here is the part that deserves more weight than it usually gets.
IGF-1 is a growth signal. It does not distinguish between tissue you want larger and tissue you do not.
A 1995 study infused Long R3 IGF-1 into guinea pigs and measured organ weights. The adrenals, gut, kidneys and spleen all grew significantly relative to controls. That is the same signal producing the same response in tissues nobody was targeting.
And a 2026 study is worth sitting with. Rats with volumetric muscle loss received IGF-1 LR3 in a hydrogel. Muscle weight increased at high doses. But there was no measurable improvement in muscle function, fibre size, or fibre count. Mass went up. Nothing that mass is supposed to deliver went up with it.
More growth signal does not automatically mean more useful tissue.
IGF-1 signalling is implicated in cancer biology, and there is human epidemiological data rather than only mechanism.
One meta-analysis pooled individual data from 17 prospective studies and more than 10,000 prostate cancer cases. Higher circulating IGF-1 was linked to higher risk, with an odds ratio of about 1.29 comparing the top fifth to the bottom. Similar links have been reported for breast and colorectal cancer.
That is an association in people whose levels vary naturally. It is not a demonstration that injecting IGF-1 causes cancer. But it is the kind of evidence that should give pause before holding levels above the natural range for long stretches.
Direct IGF-1 has one approved use. It treats a rare genetic condition in which growth hormone receptors do not work, so the liver cannot turn growth hormone into IGF-1. There, supplying the downstream hormone makes sense, because the upstream step is broken.
Outside that, it is not part of mainstream practice, and the reason is structural. If someone's own axis is working, the way to raise IGF-1 is to signal upstream and let the body make it. The feedback loops, the natural rhythm and the binding proteins all stay in place. Injecting the end product bypasses every one of those controls.
That is worth knowing if a clinic offers direct IGF-1 for general "optimisation." The molecule was built to escape regulation. In a healthy person, escaping regulation is not obviously what you want from a growth signal.
It is also prohibited by WADA, under peptide hormones and growth factors.
There are no published dose-finding studies in healthy people for this analogue by injection. The human data is one forearm infusion study of the native hormone from 1994. Everything else is animals, cells, or inference from how the modification changes binding.
Nobody has studied what sustained above-normal IGF-1 does over the long run in this context. That covers cardiac tissue, the gut, insulin sensitivity and proliferative risk. The guinea pig organ-growth data suggests those questions are not hypothetical.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
